Imunon, Inc. (IMNN) 10-Year Financial Performance & Capital Metrics

IMNN • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutImunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.Show more

Revenue $0
EBITDA -$18M +9.3%
Net Income -$19M +4.6%
EPS (Diluted) -21.10 +25.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -211.21% -131.2%
ROIC -330.45% -248.6%
Debt/Equity 0.27 +121.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 0/9
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Shares diluted 27.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM26.33%

EPS CAGR

10Y-

5Y-

3Y-

TTM57.98%

ROCE

10Y Avg-71.29%

5Y Avg-87.2%

3Y Avg-110.89%

Latest-196.65%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	500K	500K	500K	500K	500K	500K	500K	500K	0	0
Revenue Growth %	0%	0%	0%	0%	0%	0%	0%	0%	-1%	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	500K	500K	500K	500K	500K	500K	500K	500K	0	0
Gross Margin %	1%	1%	1%	1%	1%	1%	1%	1%	-	-
Gross Profit Growth %	0%	0%	0%	0%	0%	0%	0%	0%	-1%	-
Operating Expenses+	21.35M	21.15M	18.97M	21.57M	21.07M	18.99M	21.51M	25.42M	21.03M	19.13M
OpEx % of Revenue	42.69%	42.3%	37.94%	43.13%	42.13%	37.97%	43.01%	50.84%	-	-
Selling, General & Admin	6.69M	6.53M	5.89M	9.7M	8M	7.64M	10.89M	13.69M	9.74M	7.49M
SG&A % of Revenue	13.37%	13.05%	11.78%	19.4%	16%	15.28%	21.78%	27.38%	-	-
Research & Development	14.66M	14.62M	13.08M	11.87M	13.07M	11.34M	10.62M	11.73M	11.29M	11.64M
R&D % of Revenue	29.32%	29.25%	26.16%	23.73%	26.13%	22.69%	21.24%	23.47%	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-20.85M	-20.65M	-18.47M	-21.07M	-20.57M	-18.49M	-21.01M	-24.92M	-21.03M	-19.13M
Operating Margin %	-41.69%	-41.3%	-36.94%	-42.13%	-41.13%	-36.97%	-42.01%	-49.84%	-	-
Operating Income Growth %	0.16%	0.01%	0.11%	-0.14%	0.02%	0.1%	-0.14%	-0.19%	0.16%	0.09%
EBITDA+	-20.42M	-19.63M	-17.92M	-20.71M	-19.84M	-17.74M	-20.3M	-24.19M	-20.31M	-18.41M
EBITDA Margin %	-40.84%	-39.25%	-35.83%	-41.42%	-39.69%	-35.49%	-40.61%	-48.38%	-	-
EBITDA Growth %	0.16%	0.04%	0.09%	-0.16%	0.04%	0.11%	-0.14%	-0.19%	0.16%	0.09%
D&A (Non-Cash Add-back)	424.97K	1.02M	553.01K	356.86K	721.66K	741.52K	702.92K	731.63K	720K	718.12K
EBIT	-21.1M	-21.33M	-20.31M	-21.59M	-17.27M	-22.04M	-21.58M	-32.44M	-20.6M	-18.62M
Net Interest Income+	-1.17M	-691.73K	-65.72K	-348.18K	-950.41K	-1.23M	-551.74K	-4.53M	528.74K	450.22K
Interest Income	186.32K	31.26K	26.04K	363.85K	442.99K	66.55K	18.14K	502.58K	725.82K	450.22K
Interest Expense	1.36M	722.99K	91.76K	712.02K	1.39M	1.29M	569.88K	5.03M	197.08K	0
Other Income/Expense	-1.61M	-1.4M	-1.93M	-1.24M	1.9M	-4.84M	-1.15M	-12.54M	235.07K	512.2K
Pretax Income+	-22.46M	-22.05M	-20.4M	-22.3M	-18.67M	-23.33M	-22.15M	-37.47M	-20.8M	-18.62M
Pretax Margin %	-44.92%	-44.11%	-40.8%	-44.6%	-37.34%	-46.66%	-44.31%	-74.93%	-	-
Income Tax+	0	0	0	-10.42M	-1.82M	-1.85M	-1.38M	-1.57M	-1.28M	0
Effective Tax Rate %	1%	1%	1%	0.53%	0.9%	0.92%	0.94%	0.96%	0.94%	1%
Net Income+	-22.46M	-22.05M	-20.4M	-11.88M	-16.85M	-21.48M	-20.77M	-35.9M	-19.51M	-18.62M
Net Margin %	-44.92%	-44.11%	-40.8%	-23.77%	-33.7%	-42.97%	-41.54%	-71.8%	-	-
Net Income Growth %	0.12%	0.02%	0.07%	0.42%	-0.42%	-0.27%	0.03%	-0.73%	0.46%	0.05%
Net Income (Continuing)	-22.46M	-22.05M	-20.4M	-11.88M	-16.85M	-21.48M	-20.77M	-35.9M	-19.51M	-18.62M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2821.30	-2328.26	-532.22	-132.23	-151.01	-131.51	-748.77	-65.55	-28.14	-21.10
EPS Growth %	0.25%	0.17%	0.77%	0.75%	-0.14%	0.13%	-4.69%	0.91%	0.57%	0.25%
EPS (Basic)	-2821.30	-2328.26	-532.22	-132.23	-151.01	-131.51	-748.77	-65.55	-28.14	-21.10
Diluted Shares Outstanding	7.96K	9.48K	38.98K	89.87K	111.59K	163.36K	27.74K	547.63K	693.47K	882.29K
Basic Shares Outstanding	7.96K	9.48K	38.98K	89.87K	111.59K	163.36K	27.74K	547.63K	693.47K	882.29K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	20.28M	4.51M	24.31M	28.13M	16.24M	18.82M	51.95M	36.78M	18.24M	8.01M
Cash & Short-Term Investments	20.07M	4.3M	24.17M	27.61M	14.86M	17.16M	49.39M	32.75M	15.7M	5.87M
Cash Only	9.27M	2.62M	11.44M	13.35M	6.88M	17.16M	19.59M	11.49M	5.84M	5.87M
Short-Term Investments	10.8M	1.68M	12.72M	14.26M	7.99M	0	29.8M	21.25M	9.86M	0
Accounts Receivable	26.73K	4.01K	54.44K	68.31K	21.37K	0	108.84K	128.93K	0	0
Days Sales Outstanding	19.51	2.93	39.74	49.87	15.6	-	79.46	94.12	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	100.37K	115.22K	0	0	0	0	0	3.9M	2.55M	2.14M
Total Non-Current Assets+	28.75M	26.34M	23.2M	18.72M	22.04M	18.7M	22.1M	7.2M	3.68M	1.71M
Property, Plant & Equipment	854.87K	462.84K	175.77K	184.63K	1.84M	1.34M	1.17M	704.18K	2.35M	1.66M
Fixed Asset Turnover	0.58x	1.08x	2.84x	2.71x	0.27x	0.37x	0.43x	0.71x	-	-
Goodwill	1.98M	1.98M	1.98M	1.98M	1.98M	1.98M	0	0	0	0
Intangible Assets	25.8M	23.79M	21.04M	16.3M	16.08M	13.48M	13.37M	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	114.39K	108.76K	8.76K	258.93K	333.27K	58.76K	6.18M	4.92M	50K	50K
Total Assets+	49.03M	30.85M	47.51M	46.86M	38.28M	37.53M	74.05M	43.98M	21.92M	9.72M
Asset Turnover	0.01x	0.02x	0.01x	0.01x	0.01x	0.01x	0.01x	0.01x	-	-
Asset Growth %	-0.26%	-0.37%	0.54%	-0.01%	-0.18%	-0.02%	0.97%	-0.41%	-0.5%	-0.56%
Total Current Liabilities+	9.32M	8.42M	6.2M	6.11M	7.89M	6.75M	6.77M	10.04M	7.39M	4.79M
Accounts Payable	2.83M	2.88M	3.42M	3.02M	2.86M	2.24M	2.55M	3.59M	3.52M	1.3M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	4.07M	2.56M	0	0	1.84M	1.12M	0	1.42M	0	0
Deferred Revenue (Current)	500K	500K	500K	500K	500K	500K	500K	0	0	0
Other Current Liabilities	0	0	0	0	0	0	0	0	0	0
Current Ratio	2.18x	0.54x	3.92x	4.61x	2.06x	2.79x	7.67x	3.66x	2.47x	1.67x
Quick Ratio	2.18x	0.54x	3.92x	4.61x	2.06x	2.79x	7.67x	3.66x	2.47x	1.67x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	19.32M	15.7M	14.61M	19.89M	15.82M	12.16M	11.48M	4.61M	1.14M	686.93K
Long-Term Debt	2.35M	0	0	9.42M	7.96M	3.93M	5.85M	4.61M	0	0
Capital Lease Obligations	0	0	0	0	1.14M	710.3K	230.75K	0	1.14M	686.93K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	13.97M	13.2M	12.61M	8.97M	5.72M	7.02M	5.4M	0	0	0
Total Liabilities	28.64M	24.12M	20.81M	25.99M	23.72M	18.92M	18.25M	14.65M	8.53M	5.47M
Total Debt+	6.42M	2.56M	0	9.42M	11.34M	6.19M	6.63M	6.27M	1.62M	1.14M
Net Debt	-2.84M	-63.61K	-11.44M	-3.94M	4.46M	-10.97M	-12.95M	-5.23M	-4.21M	-4.73M
Debt / Equity	0.32x	0.38x	-	0.45x	0.78x	0.33x	0.12x	0.21x	0.12x	0.27x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-15.36x	-28.56x	-201.28x	-29.58x	-14.76x	-14.30x	-36.86x	-4.96x	-106.71x	-
Total Equity+	20.39M	6.73M	26.7M	20.86M	14.56M	18.61M	55.8M	29.33M	13.39M	4.24M
Equity Growth %	-0.38%	-0.67%	2.97%	-0.22%	-0.3%	0.28%	2%	-0.47%	-0.54%	-0.68%
Book Value per Share	2560.05	709.77	685.03	232.13	130.47	113.93	2011.61	53.55	19.31	4.81
Total Shareholders' Equity	20.39M	6.73M	26.7M	20.86M	14.56M	18.61M	55.8M	29.33M	13.39M	4.24M
Common Stock	233.95K	22.3K	172.77K	188.32K	232.56K	27.13K	57.7K	74.36K	94K	145.01K
Retained Earnings	-218.13M	-241.38M	-261.78M	-273.67M	-290.52M	-312M	-332.77M	-368.67M	-388.18M	-406.8M
Treasury Stock	-1.38M	-85.19K	-85.19K	-85.19K	-85.19K	-85.19K	-85.19K	-85.19K	-85.19K	-85.19K
Accumulated OCI	-3.86K	0	-10.16K	29.87K	42.78K	0	-7.97K	26.49K	60.8K	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.83M	-18.38M	-16.64M	-7.04M	-20.26M	-15.62M	-16.22M	-23.1M	-19.02M	-18.85M
Operating CF Margin %	-41.66%	-36.76%	-33.28%	-14.08%	-40.52%	-31.24%	-32.45%	-46.19%	-	-
Operating CF Growth %	0.02%	0.12%	0.09%	0.58%	-1.88%	0.23%	-0.04%	-0.42%	0.18%	0.01%
Net Income	-22.46M	-22.05M	-20.4M	-11.88M	-16.85M	-21.48M	-20.77M	-35.9M	-19.51M	-18.62M
Depreciation & Amortization	424.97K	1.02M	553.01K	356.86K	721.66K	741.52K	702.92K	731.63K	720K	718.12K
Stock-Based Compensation	1.85M	1.51M	1.11M	4.6M	2.29M	1.85M	3.76M	2.67M	759.01K	477.26K
Deferred Taxes	0	0	0	0	-1.82M	-26.5K	462.38K	-183.58K	286.64K	1.28M
Other Non-Cash Items	821.82K	1.02M	2.2M	1.1M	-2.4M	4.16M	591.36K	7.69M	793.58K	-61.98K
Working Capital Changes	-1.47M	120.6K	-98.25K	-1.22M	-2.2M	-864.36K	-970.74K	1.89M	-2.07M	-2.65M
Change in Receivables	183.3K	22.72K	-50.43K	-13.87K	46.94K	21.37K	-108.84K	-20.09K	68.14K	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-859.18K	48.75K	537.88K	-396.23K	-157.69K	-618.1K	302.4K	1.04M	0	-3.06M
Cash from Investing+	13.33M	9.06M	-10.99M	-1.63M	5.94M	7.92M	-30.12M	8.28M	11.01M	9.83M
Capital Expenditures	-109.34K	-62.5K	-38.63K	-138.4K	-349.16K	-19.09K	-311.61K	-267.8K	-451.76K	-29.54K
CapEx % of Revenue	0.22%	0.13%	0.08%	0.28%	0.7%	0.04%	0.62%	0.54%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	50K	0	100K	0	0	0	0	0	0	0
Cash from Financing+	4.08M	2.68M	36.45M	10.58M	7.84M	17.98M	54.77M	6.72M	-3.64M	9.06M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	2.5K	21.14M	0	0	371.89K	1.51M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-20.94M	-18.44M	-16.68M	-7.18M	-20.61M	-15.64M	-16.54M	-23.36M	-19.47M	-18.88M
FCF Margin %	-41.88%	-36.88%	-33.36%	-14.36%	-41.22%	-31.28%	-33.07%	-46.73%	-	-
FCF Growth %	0.05%	0.12%	0.1%	0.57%	-1.87%	0.24%	-0.06%	-0.41%	0.17%	0.03%
FCF per Share	-2629.65	-1946.17	-427.90	-79.90	-184.68	-95.73	-596.14	-42.67	-28.08	-21.40
FCF Conversion (FCF/Net Income)	0.93x	0.83x	0.82x	0.59x	1.20x	0.73x	0.78x	0.64x	0.97x	1.01x
Interest Paid	918.47K	486.33K	56.39K	512.87K	1.01M	844.28K	357.28K	4.85M	179.54K	0
Taxes Paid	0	0	0	0	0	0	0	2K	2.5K	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-84.42%	-162.69%	-122.06%	-49.97%	-95.15%	-129.54%	-55.83%	-84.34%	-91.37%	-211.21%
Return on Invested Capital (ROIC)	-65.98%	-127.96%	-126.37%	-98.17%	-85.82%	-104.01%	-62.42%	-55.84%	-94.8%	-330.45%
Gross Margin	100%	100%	100%	100%	100%	100%	100%	100%	-	-
Net Margin	-4492.22%	-4410.75%	-4080.44%	-2376.67%	-3370.31%	-4296.71%	-4153.85%	-7179.65%	-	-
Debt / Equity	0.32x	0.38x	-	0.45x	0.78x	0.33x	0.12x	0.21x	0.12x	0.27x
Interest Coverage	-15.36x	-28.56x	-201.28x	-29.58x	-14.76x	-14.30x	-36.86x	-4.96x	-106.71x	-
FCF Conversion	0.93x	0.83x	0.82x	0.59x	1.20x	0.73x	0.78x	0.64x	0.97x	1.01x
Revenue Growth	0%	0%	0%	0%	0%	0%	0%	0%	-100%	-

Frequently Asked Questions

Growth & Financials

Imunon, Inc. (IMNN) grew revenue by 0.0% over the past year. Growth has been modest.

Imunon, Inc. (IMNN) reported a net loss of $14.3M for fiscal year 2024.

Dividend & Returns

Imunon, Inc. (IMNN) has a return on equity (ROE) of -211.2%. Negative ROE indicates the company is unprofitable.

Imunon, Inc. (IMNN) had negative free cash flow of $15.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Imunon, Inc. (IMNN) 10-Year Financial Performance & Capital Metrics

IMNN • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$18M +9.3%
Net Income -$19M +4.6%
EPS (Diluted) -21.10 +25.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -211.21% -131.2%
ROIC -330.45% -248.6%
Debt/Equity 0.27 +121.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 0/9
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Shares diluted 27.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM26.33%

EPS CAGR

10Y-

5Y-

3Y-

TTM57.98%

ROCE

10Y Avg-71.29%

5Y Avg-87.2%

3Y Avg-110.89%

Latest-196.65%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	500K	500K	500K	500K	500K	500K	500K	500K	0	0
Revenue Growth %	0%	0%	0%	0%	0%	0%	0%	0%	-1%	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	500K	500K	500K	500K	500K	500K	500K	500K	0	0
Gross Margin %	1%	1%	1%	1%	1%	1%	1%	1%	-	-
Gross Profit Growth %	0%	0%	0%	0%	0%	0%	0%	0%	-1%	-
Operating Expenses+	21.35M	21.15M	18.97M	21.57M	21.07M	18.99M	21.51M	25.42M	21.03M	19.13M
OpEx % of Revenue	42.69%	42.3%	37.94%	43.13%	42.13%	37.97%	43.01%	50.84%	-	-
Selling, General & Admin	6.69M	6.53M	5.89M	9.7M	8M	7.64M	10.89M	13.69M	9.74M	7.49M
SG&A % of Revenue	13.37%	13.05%	11.78%	19.4%	16%	15.28%	21.78%	27.38%	-	-
Research & Development	14.66M	14.62M	13.08M	11.87M	13.07M	11.34M	10.62M	11.73M	11.29M	11.64M
R&D % of Revenue	29.32%	29.25%	26.16%	23.73%	26.13%	22.69%	21.24%	23.47%	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-20.85M	-20.65M	-18.47M	-21.07M	-20.57M	-18.49M	-21.01M	-24.92M	-21.03M	-19.13M
Operating Margin %	-41.69%	-41.3%	-36.94%	-42.13%	-41.13%	-36.97%	-42.01%	-49.84%	-	-
Operating Income Growth %	0.16%	0.01%	0.11%	-0.14%	0.02%	0.1%	-0.14%	-0.19%	0.16%	0.09%
EBITDA+	-20.42M	-19.63M	-17.92M	-20.71M	-19.84M	-17.74M	-20.3M	-24.19M	-20.31M	-18.41M
EBITDA Margin %	-40.84%	-39.25%	-35.83%	-41.42%	-39.69%	-35.49%	-40.61%	-48.38%	-	-
EBITDA Growth %	0.16%	0.04%	0.09%	-0.16%	0.04%	0.11%	-0.14%	-0.19%	0.16%	0.09%
D&A (Non-Cash Add-back)	424.97K	1.02M	553.01K	356.86K	721.66K	741.52K	702.92K	731.63K	720K	718.12K
EBIT	-21.1M	-21.33M	-20.31M	-21.59M	-17.27M	-22.04M	-21.58M	-32.44M	-20.6M	-18.62M
Net Interest Income+	-1.17M	-691.73K	-65.72K	-348.18K	-950.41K	-1.23M	-551.74K	-4.53M	528.74K	450.22K
Interest Income	186.32K	31.26K	26.04K	363.85K	442.99K	66.55K	18.14K	502.58K	725.82K	450.22K
Interest Expense	1.36M	722.99K	91.76K	712.02K	1.39M	1.29M	569.88K	5.03M	197.08K	0
Other Income/Expense	-1.61M	-1.4M	-1.93M	-1.24M	1.9M	-4.84M	-1.15M	-12.54M	235.07K	512.2K
Pretax Income+	-22.46M	-22.05M	-20.4M	-22.3M	-18.67M	-23.33M	-22.15M	-37.47M	-20.8M	-18.62M
Pretax Margin %	-44.92%	-44.11%	-40.8%	-44.6%	-37.34%	-46.66%	-44.31%	-74.93%	-	-
Income Tax+	0	0	0	-10.42M	-1.82M	-1.85M	-1.38M	-1.57M	-1.28M	0
Effective Tax Rate %	1%	1%	1%	0.53%	0.9%	0.92%	0.94%	0.96%	0.94%	1%
Net Income+	-22.46M	-22.05M	-20.4M	-11.88M	-16.85M	-21.48M	-20.77M	-35.9M	-19.51M	-18.62M
Net Margin %	-44.92%	-44.11%	-40.8%	-23.77%	-33.7%	-42.97%	-41.54%	-71.8%	-	-
Net Income Growth %	0.12%	0.02%	0.07%	0.42%	-0.42%	-0.27%	0.03%	-0.73%	0.46%	0.05%
Net Income (Continuing)	-22.46M	-22.05M	-20.4M	-11.88M	-16.85M	-21.48M	-20.77M	-35.9M	-19.51M	-18.62M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2821.30	-2328.26	-532.22	-132.23	-151.01	-131.51	-748.77	-65.55	-28.14	-21.10
EPS Growth %	0.25%	0.17%	0.77%	0.75%	-0.14%	0.13%	-4.69%	0.91%	0.57%	0.25%
EPS (Basic)	-2821.30	-2328.26	-532.22	-132.23	-151.01	-131.51	-748.77	-65.55	-28.14	-21.10
Diluted Shares Outstanding	7.96K	9.48K	38.98K	89.87K	111.59K	163.36K	27.74K	547.63K	693.47K	882.29K
Basic Shares Outstanding	7.96K	9.48K	38.98K	89.87K	111.59K	163.36K	27.74K	547.63K	693.47K	882.29K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	20.28M	4.51M	24.31M	28.13M	16.24M	18.82M	51.95M	36.78M	18.24M	8.01M
Cash & Short-Term Investments	20.07M	4.3M	24.17M	27.61M	14.86M	17.16M	49.39M	32.75M	15.7M	5.87M
Cash Only	9.27M	2.62M	11.44M	13.35M	6.88M	17.16M	19.59M	11.49M	5.84M	5.87M
Short-Term Investments	10.8M	1.68M	12.72M	14.26M	7.99M	0	29.8M	21.25M	9.86M	0
Accounts Receivable	26.73K	4.01K	54.44K	68.31K	21.37K	0	108.84K	128.93K	0	0
Days Sales Outstanding	19.51	2.93	39.74	49.87	15.6	-	79.46	94.12	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	100.37K	115.22K	0	0	0	0	0	3.9M	2.55M	2.14M
Total Non-Current Assets+	28.75M	26.34M	23.2M	18.72M	22.04M	18.7M	22.1M	7.2M	3.68M	1.71M
Property, Plant & Equipment	854.87K	462.84K	175.77K	184.63K	1.84M	1.34M	1.17M	704.18K	2.35M	1.66M
Fixed Asset Turnover	0.58x	1.08x	2.84x	2.71x	0.27x	0.37x	0.43x	0.71x	-	-
Goodwill	1.98M	1.98M	1.98M	1.98M	1.98M	1.98M	0	0	0	0
Intangible Assets	25.8M	23.79M	21.04M	16.3M	16.08M	13.48M	13.37M	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	114.39K	108.76K	8.76K	258.93K	333.27K	58.76K	6.18M	4.92M	50K	50K
Total Assets+	49.03M	30.85M	47.51M	46.86M	38.28M	37.53M	74.05M	43.98M	21.92M	9.72M
Asset Turnover	0.01x	0.02x	0.01x	0.01x	0.01x	0.01x	0.01x	0.01x	-	-
Asset Growth %	-0.26%	-0.37%	0.54%	-0.01%	-0.18%	-0.02%	0.97%	-0.41%	-0.5%	-0.56%
Total Current Liabilities+	9.32M	8.42M	6.2M	6.11M	7.89M	6.75M	6.77M	10.04M	7.39M	4.79M
Accounts Payable	2.83M	2.88M	3.42M	3.02M	2.86M	2.24M	2.55M	3.59M	3.52M	1.3M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	4.07M	2.56M	0	0	1.84M	1.12M	0	1.42M	0	0
Deferred Revenue (Current)	500K	500K	500K	500K	500K	500K	500K	0	0	0
Other Current Liabilities	0	0	0	0	0	0	0	0	0	0
Current Ratio	2.18x	0.54x	3.92x	4.61x	2.06x	2.79x	7.67x	3.66x	2.47x	1.67x
Quick Ratio	2.18x	0.54x	3.92x	4.61x	2.06x	2.79x	7.67x	3.66x	2.47x	1.67x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	19.32M	15.7M	14.61M	19.89M	15.82M	12.16M	11.48M	4.61M	1.14M	686.93K
Long-Term Debt	2.35M	0	0	9.42M	7.96M	3.93M	5.85M	4.61M	0	0
Capital Lease Obligations	0	0	0	0	1.14M	710.3K	230.75K	0	1.14M	686.93K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	13.97M	13.2M	12.61M	8.97M	5.72M	7.02M	5.4M	0	0	0
Total Liabilities	28.64M	24.12M	20.81M	25.99M	23.72M	18.92M	18.25M	14.65M	8.53M	5.47M
Total Debt+	6.42M	2.56M	0	9.42M	11.34M	6.19M	6.63M	6.27M	1.62M	1.14M
Net Debt	-2.84M	-63.61K	-11.44M	-3.94M	4.46M	-10.97M	-12.95M	-5.23M	-4.21M	-4.73M
Debt / Equity	0.32x	0.38x	-	0.45x	0.78x	0.33x	0.12x	0.21x	0.12x	0.27x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-15.36x	-28.56x	-201.28x	-29.58x	-14.76x	-14.30x	-36.86x	-4.96x	-106.71x	-
Total Equity+	20.39M	6.73M	26.7M	20.86M	14.56M	18.61M	55.8M	29.33M	13.39M	4.24M
Equity Growth %	-0.38%	-0.67%	2.97%	-0.22%	-0.3%	0.28%	2%	-0.47%	-0.54%	-0.68%
Book Value per Share	2560.05	709.77	685.03	232.13	130.47	113.93	2011.61	53.55	19.31	4.81
Total Shareholders' Equity	20.39M	6.73M	26.7M	20.86M	14.56M	18.61M	55.8M	29.33M	13.39M	4.24M
Common Stock	233.95K	22.3K	172.77K	188.32K	232.56K	27.13K	57.7K	74.36K	94K	145.01K
Retained Earnings	-218.13M	-241.38M	-261.78M	-273.67M	-290.52M	-312M	-332.77M	-368.67M	-388.18M	-406.8M
Treasury Stock	-1.38M	-85.19K	-85.19K	-85.19K	-85.19K	-85.19K	-85.19K	-85.19K	-85.19K	-85.19K
Accumulated OCI	-3.86K	0	-10.16K	29.87K	42.78K	0	-7.97K	26.49K	60.8K	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.83M	-18.38M	-16.64M	-7.04M	-20.26M	-15.62M	-16.22M	-23.1M	-19.02M	-18.85M
Operating CF Margin %	-41.66%	-36.76%	-33.28%	-14.08%	-40.52%	-31.24%	-32.45%	-46.19%	-	-
Operating CF Growth %	0.02%	0.12%	0.09%	0.58%	-1.88%	0.23%	-0.04%	-0.42%	0.18%	0.01%
Net Income	-22.46M	-22.05M	-20.4M	-11.88M	-16.85M	-21.48M	-20.77M	-35.9M	-19.51M	-18.62M
Depreciation & Amortization	424.97K	1.02M	553.01K	356.86K	721.66K	741.52K	702.92K	731.63K	720K	718.12K
Stock-Based Compensation	1.85M	1.51M	1.11M	4.6M	2.29M	1.85M	3.76M	2.67M	759.01K	477.26K
Deferred Taxes	0	0	0	0	-1.82M	-26.5K	462.38K	-183.58K	286.64K	1.28M
Other Non-Cash Items	821.82K	1.02M	2.2M	1.1M	-2.4M	4.16M	591.36K	7.69M	793.58K	-61.98K
Working Capital Changes	-1.47M	120.6K	-98.25K	-1.22M	-2.2M	-864.36K	-970.74K	1.89M	-2.07M	-2.65M
Change in Receivables	183.3K	22.72K	-50.43K	-13.87K	46.94K	21.37K	-108.84K	-20.09K	68.14K	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-859.18K	48.75K	537.88K	-396.23K	-157.69K	-618.1K	302.4K	1.04M	0	-3.06M
Cash from Investing+	13.33M	9.06M	-10.99M	-1.63M	5.94M	7.92M	-30.12M	8.28M	11.01M	9.83M
Capital Expenditures	-109.34K	-62.5K	-38.63K	-138.4K	-349.16K	-19.09K	-311.61K	-267.8K	-451.76K	-29.54K
CapEx % of Revenue	0.22%	0.13%	0.08%	0.28%	0.7%	0.04%	0.62%	0.54%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	50K	0	100K	0	0	0	0	0	0	0
Cash from Financing+	4.08M	2.68M	36.45M	10.58M	7.84M	17.98M	54.77M	6.72M	-3.64M	9.06M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	2.5K	21.14M	0	0	371.89K	1.51M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-20.94M	-18.44M	-16.68M	-7.18M	-20.61M	-15.64M	-16.54M	-23.36M	-19.47M	-18.88M
FCF Margin %	-41.88%	-36.88%	-33.36%	-14.36%	-41.22%	-31.28%	-33.07%	-46.73%	-	-
FCF Growth %	0.05%	0.12%	0.1%	0.57%	-1.87%	0.24%	-0.06%	-0.41%	0.17%	0.03%
FCF per Share	-2629.65	-1946.17	-427.90	-79.90	-184.68	-95.73	-596.14	-42.67	-28.08	-21.40
FCF Conversion (FCF/Net Income)	0.93x	0.83x	0.82x	0.59x	1.20x	0.73x	0.78x	0.64x	0.97x	1.01x
Interest Paid	918.47K	486.33K	56.39K	512.87K	1.01M	844.28K	357.28K	4.85M	179.54K	0
Taxes Paid	0	0	0	0	0	0	0	2K	2.5K	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-84.42%	-162.69%	-122.06%	-49.97%	-95.15%	-129.54%	-55.83%	-84.34%	-91.37%	-211.21%
Return on Invested Capital (ROIC)	-65.98%	-127.96%	-126.37%	-98.17%	-85.82%	-104.01%	-62.42%	-55.84%	-94.8%	-330.45%
Gross Margin	100%	100%	100%	100%	100%	100%	100%	100%	-	-
Net Margin	-4492.22%	-4410.75%	-4080.44%	-2376.67%	-3370.31%	-4296.71%	-4153.85%	-7179.65%	-	-
Debt / Equity	0.32x	0.38x	-	0.45x	0.78x	0.33x	0.12x	0.21x	0.12x	0.27x
Interest Coverage	-15.36x	-28.56x	-201.28x	-29.58x	-14.76x	-14.30x	-36.86x	-4.96x	-106.71x	-
FCF Conversion	0.93x	0.83x	0.82x	0.59x	1.20x	0.73x	0.78x	0.64x	0.97x	1.01x
Revenue Growth	0%	0%	0%	0%	0%	0%	0%	0%	-100%	-

Frequently Asked Questions

Growth & Financials

Imunon, Inc. (IMNN) grew revenue by 0.0% over the past year. Growth has been modest.

Imunon, Inc. (IMNN) reported a net loss of $14.3M for fiscal year 2024.

Dividend & Returns

Imunon, Inc. (IMNN) has a return on equity (ROE) of -211.2%. Negative ROE indicates the company is unprofitable.

Imunon, Inc. (IMNN) had negative free cash flow of $15.0M in fiscal year 2024, likely due to heavy capital investments.